Literature DB >> 29296949

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.

Kate H Gartlan1,2, Antiopi Varelias1,2, Motoko Koyama1, Renee J Robb1, Kate A Markey1,2,3, Karshing Chang1, Andrew N Wilkinson1,2, David Smith1, Md Ashik Ullah1, Rachel D Kuns1, Neil C Raffelt1, Stuart D Olver1, Katie E Lineburg1, Bianca E Teal1, Melody Cheong1, Michele W L Teng1, Mark J Smyth1,2, Siok-Keen Tey1,2,3, Kelli P A MacDonald1, Geoffrey R Hill1,3.   

Abstract

T-helper 17 (Th17) cells have been widely implicated as drivers of autoimmune disease. In particular, Th17 cytokine plasticity and acquisition of an interleukin-17A+(IL-17A+)interferon γ(IFNγ)+ cytokine profile is associated with increased pathogenic capacity. Donor Th17 polarization is known to exacerbate graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT); however, donor Th17 cytokine coexpression and plasticity have not been fully characterized. Using IL-17 "fate-mapping" mice, we identified IL-6-dependent Th17 cells early after allo-SCT, characterized by elevated expression of proinflammatory cytokines, IL-17A, IL-22, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor. This population did not maintain lineage fidelity, with a marked loss of IL-17A and IL-22 expression late posttransplant. Th17 cells were further segregated based on IFNγ coexpression, and IL-17A+IFNγ+ Th17 displayed an enhanced proinflammatory phenotype. Th17 cytokine plasticity and IFNγ production were critically dependent upon donor-derived IL-12p40, and cyclosporine (CsA) treatment regulated this differentiation pathway. This observation was highly concordant with clinical samples from allo-SCT recipients receiving CsA-based immune suppression where although the IFNγ-negative-Th17 subset predominated, IFNγ+-Th17 cells were also present. In sum, Th17 polarization and ensuing differentiation are mediated by sequential inflammatory signals, which are modulated by immunosuppressive therapy, leading to distinct phenotypes within this lineage.

Entities:  

Year:  2017        PMID: 29296949      PMCID: PMC5738990          DOI: 10.1182/bloodadvances.2016002980

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  48 in total

Review 1.  Essentials of Th17 cell commitment and plasticity.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 2.  Th17 cells in immunity to Candida albicans.

Authors:  Nydiaris Hernández-Santos; Sarah L Gaffen
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

Review 3.  The IL-17 differentiation pathway and its role in transplant outcome.

Authors:  Jonathan S Serody; Geoffrey R Hill
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

4.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

5.  Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells.

Authors:  Gang Wei; Lai Wei; Jinfang Zhu; Chongzhi Zang; Jane Hu-Li; Zhengju Yao; Kairong Cui; Yuka Kanno; Tae-Young Roh; Wendy T Watford; Dustin E Schones; Weiqun Peng; Hong-Wei Sun; William E Paul; John J O'Shea; Keji Zhao
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

6.  Ciclosporin A inhibits production of interleukin-12/23p40 and interleukin-23 by the human monocyte cell line, THP-1.

Authors:  M Kamata; Y Tada; A Tatsuta; T Kawashima; S Shibata; H Mitsui; Y Asano; M Sugaya; T Kadono; N Kanda; S Watanabe; S Sato
Journal:  Clin Exp Dermatol       Date:  2013-07       Impact factor: 3.470

Review 7.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

8.  IL-17 contributes to CD4-mediated graft-versus-host disease.

Authors:  Lucy W Kappel; Gabrielle L Goldberg; Christopher G King; David Y Suh; Odette M Smith; Cassandra Ligh; Amanda M Holland; Jeremy Grubin; Nicholas M Mark; Chen Liu; Yoichiro Iwakura; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

9.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling.

Authors:  Kamran Ghoreschi; Arian Laurence; Xiang-Ping Yang; Cristina M Tato; Mandy J McGeachy; Joanne E Konkel; Haydeé L Ramos; Lai Wei; Todd S Davidson; Nicolas Bouladoux; John R Grainger; Qian Chen; Yuka Kanno; Wendy T Watford; Hong-Wei Sun; Gérard Eberl; Ethan M Shevach; Yasmine Belkaid; Daniel J Cua; Wanjun Chen; John J O'Shea
Journal:  Nature       Date:  2010-10-21       Impact factor: 49.962

View more
  12 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Expansion of IL-17A-secreting CD8+ mucosa-associated invariant T cells in peripheral blood following stem cell mobilization.

Authors:  Antiopi Varelias; Kate H Gartlan; Andrew N Wilkinson; Stuart D Olver; Luke D Samson; Siok-Keen Tey; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood Adv       Date:  2019-03-12

Review 3.  The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.

Authors:  Motoko Koyama; Geoffrey R Hill
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

4.  A critical role for donor-derived IL-22 in cutaneous chronic GVHD.

Authors:  Kate H Gartlan; Hemamalini Bommiasamy; Katelyn Paz; Andrew N Wilkinson; Mary Owen; Dawn K Reichenbach; Tatjana Banovic; Kimberly Wehner; Faith Buchanan; Antiopi Varelias; Rachel D Kuns; Karshing Chang; Yuri Fedoriw; Thomas Shea; James Coghill; Michael Zaiken; Maximilian W Plank; Paul S Foster; Andrew D Clouston; Bruce R Blazar; Jonathan S Serody; Geoffrey R Hill
Journal:  Am J Transplant       Date:  2017-10-24       Impact factor: 8.086

Review 5.  Biological and clinical significance of T helper 17 cell plasticity.

Authors:  Alessio Mazzoni; Laura Maggi; Francesco Liotta; Lorenzo Cosmi; Francesco Annunziato
Journal:  Immunology       Date:  2019-10-14       Impact factor: 7.397

6.  Single-cell transcriptomics of alloreactive CD4+ T cells over time reveals divergent fates during gut graft-versus-host disease.

Authors:  Jessica A Engel; Hyun Jae Lee; Cameron G Williams; Rachel Kuns; Stuart Olver; Lianne Im Lansink; Megan Sf Soon; Stacey B Andersen; Joseph E Powell; Valentine Svensson; Sarah A Teichmann; Geoffrey R Hill; Antiopi Varelias; Motoko Koyama; Ashraful Haque
Journal:  JCI Insight       Date:  2020-07-09

7.  Donor T-cell-derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract.

Authors:  Kate H Gartlan; Motoko Koyama; Katie E Lineburg; Karshing Chang; Kathleen S Ensbey; Rachel D Kuns; Andrea S Henden; Luke D Samson; Andrew D Clouston; Angel F Lopez; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood Adv       Date:  2019-10-08

8.  T cell populations in children with autism spectrum disorder and co-morbid gastrointestinal symptoms.

Authors:  Destanie R Rose; Houa Yang; Milo Careaga; Kathy Angkustsiri; Judy Van de Water; Paul Ashwood
Journal:  Brain Behav Immun Health       Date:  2020-01-26

9.  Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD.

Authors:  Maura H Parker; Diane Stone; Kraig Abrams; Melissa Johnson; Noa Granot; Rainer Storb
Journal:  Transplantation       Date:  2021-05-01       Impact factor: 5.385

Review 10.  Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.

Authors:  Leslie S Kean
Journal:  Blood       Date:  2018-05-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.